Vaxcyte, Inc.
NASDAQPCVX reports Q1 2026 results after the close today, with one of the more committed short positions in mid-cap biotech setting the backdrop. Short sellers hold roughly 10.8% of the free float — up 8.7% over the past month alone. That is not a position built casually. Days to cover have extended to nearly 12 days using FINRA's latest official count, meaning any forced covering would…
Snapshot as of 7 May 2026
PCVX reports Q1 2026 results after the close today, with one of the more committed short positions in mid-cap biotech setting the backdrop. Short sellers hold roughly 10.8% of the free float — up 8.7% over the past…
PCVX reported Q1 2026 results after the close on May 6 — an EPS of -$2.30 against a -$1.82 consensus estimate — capping a week in which the stock already slid 5.3% to $55.64 and short interest climbed to its highest…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PCVX — free to start on ORTEX.
Sign up for free →Open PCVX on ORTEX